A glance at what’s happening in the world of technology.
1. Tiny implant for rare, sight-robbing disease shows efficacy
The first Food and Drug Administration-approved treatment for a rare, progressive retinal neurovascular and glial degenerative disease has been found to demonstrate efficacy in the latest round of trials.
Macular telangiectasia type 2 (MacTel) produces a macular photoreceptor atrophy and loss of central vision in patients.
The study, published in NEJM Evidence, investigated the efficacy and safety of revakinagene taroretcel (NT-501) in two phase III trials. These found that NT-501 resulted in a statistically significant reduced progression of ellipsoid zone area loss.
The researchers concluded that the implant may provide a protected environment for retinal pigment epithelial cells to survive and secrete therapeutic levels of ciliary neurotrophic factor.
Sign in to continue
Not already a member of the College?
Start enjoying the benefits of College membership today. Take a look at what the College can offer you and view our membership categories and rates.
The GOC is consulting on an update to its 2013 Statement on the testing of sight, alongside proposed changes to the Standards of Practice for Optometrists and Dispensing Opticians and the Standards for Optical Students.
The College of Optometrists has partnered with Boots Opticians to launch a new fully funded PhD Scholarship to extend the profession's investment in the next generation of optometry researchers.
The College of Optometrists is inviting members and non-members to nominate outstanding researchers for the annual Research Excellence Awards in recognition of those making a significant contribution to optometric research and the future of the profession.